DELRAY
BEACH, Fla., Oct. 4, 2024
/PRNewswire/ -- The global peritoneal dialysis market is set
to grow from USD 9.58 billion in 2024
to USD 12.70 billion by 2029,
reflecting a robust CAGR of 5.8%. This expansion is largely driven
by the rising prevalence of chronic kidney disease (CKD),
particularly among older populations, as well as a shift towards
home-based treatment options. Notably, about 14% of U.S. adults are
affected by CKD, with significant government support for peritoneal
dialysis in countries like China,
enhancing accessibility. Key players such as Baxter International,
Fresenius Medical Care, and Medtronic are advancing technologies to
improve patient care, yet the market faces challenges like
underutilization in low-income regions and a critical shortage of
skilled nephrologists. Emerging economies like India and Brazil present significant growth
opportunities, especially with increased healthcare expenditure.
The Asia Pacific region is
anticipated to exhibit the highest growth, fueled by an aging
population and enhanced healthcare accessibility initiatives. As
the market evolves, innovations in dialysis equipment and
telemedicine are likely to further improve patient management and
treatment outcomes, positioning peritoneal dialysis as a pivotal
component of kidney care.
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=211750966
Browse in-depth TOC on "Peritoneal Dialysis
Market"
241 - Tables
66 - Figures
252 -
Pages
In this report, the peritoneal dialysis market has been
segmented on the basis of offering, modality, disease indication,
end user and region.
The peritoneal dialysis market is segmented into peritoneal
dialysis machines, solution bags, catheters, transfer sets, other
peritoneal dialysis products and services on the basis of
offerings. Peritoneal dialysis solution bags accounted for the
largest share of global PD market, as daily dialysis dictates the
need for multiple bag consumption by every patient. In nature, as
consumables, they require constant replenishment to meet demand and
thus are constantly in high demand. Their very low cost and wide
availability make them readily used in advanced and developing
countries lacking the proper health facilities. CAPD, a "bag alone"
service that uses solution bags without dependency on equipment, is
another significant contributor to this market. PD machines,
meanwhile, are expected to grow at the highest CAGR because of
innovations that make treatment convenient enough to be done
overnight with minimal intervention. In an era when patients and
providers increasingly demand automated and home-based
alternatives, APD machines are gaining tremendous popularity,
especially in developed regions. Improved patient outcomes and
increased awareness are further fuelling the demand for PD
machines, putting the machinery in a great position to experience
rapid market growth.
The peritoneal dialysis market is segmented into continuous
ambulatory peritoneal dialysis (CAPD) and automated peritoneal
dialysis (APD) on the basis of modality. Continuous Ambulatory
Peritoneal Dialysis (CAPD) holds the largest market share of
peritoneal dialysis market. CAPD is not expensive because, unlike
hemodialysis, it does not require technical personnel or heavy
machines, and long periods of hospitalization; thus, it is much
less costly in contrast with the others when patients undergo
treatment with them. Its cost-effectiveness makes CAPD an
economically viable choice for both patients and health care
systems. CAPD does indeed lower overhead costs that the healthcare
facilities incur, especially in less developed regions with
strained resources. With ready-to-use consumables like solution
bags, CAPD smoothes the efficient use of healthcare resources for
continuation of treatment. The cost burden on patients being much
lower, health systems can use their resources much more effectively
and thus reach a larger segment of the population in need. These
cost benefits come coupled with the simplicity and autonomy that
CAPD lends to patients, which have been mainly driving a continuous
increasing trend in its adoption into a mainstay of the global
peritoneal dialysis market.
The peritoneal dialysis market is segmented into end-stage renal
disease, acute kidney injury and other disease on the basis of
disease indication. End-stage renal disease holds the largest share
in the global peritoneal dialysis market and expected to grow at
the highest CAGR. Increasing incidence of diabetes and hypertension
serve as some of the significant risk factors that contribute to
renal failure. As the prevalence of these chronic conditions
increases across different parts of the world, more people have
been developing ESRD and requiring renal replacement therapies such
as dialysis. Diabetes and hypertension may lead to chronic and
progressive damage to the kidneys, hence the need for effective
management options such as peritoneal dialysis. In comparison with
in-center hemodialysis, this modality has an added advantage to the
patient in that it allows home-based treatment, giving the patient
more flexibility and choice.
The peritoneal dialysis market is segmented into home care
settings, hospitals & independent dialysis centers and other
end user on the basis of end user. Home care settings accounted for
the largest share in the global peritoneal dialysis market and
expected to grow at the highest CAGR. Home care for dialysis saves
patients a lot of time and incurs lesser costs because frequent
hospital visits can be very tiring for patients and also costly.
With home dialysis, most of the costs associated with hospitals,
such as transportation and facility fees, are washed away, and it
becomes quite economical for patients and health care.
Cost-effectiveness, is most important in managing chronic diseases
like end-stage renal disease. Additionally, home care treatment
schedule can be more flexible and adjusted to the individual needs,
without the burden on the healthcare facilities or health care
resources at large.
The peritoneal dialysis market is segmented into North America, Europe, Asia
Pacific, Latin America,
Middle East, and Africa and GCC Countries on the basis of
geographic region. North America
holds the largest share of the peritoneal dialysis market in 2023.
North America, has a
well-developed healthcare system that can be described as having
high technology and extensive medical facilities. With these sorts
of robust infrastructures, peritoneal dialysis services are thus
delivered efficiently so that the patients are provided with good
quality care and latest innovations in their treatment. Its
hospitals and clinics are supplied with high-end apparatuses and
facilities to ensure effective management and monitoring of
dialysis procedures. Furthermore, the availability of well-trained
care providers who specialize in nephrology increases the result
outcome as they can handle various cases that are peculiar to
individuals. Such an advanced healthcare scenario facilitates the
adoption of peritoneal dialysis with the discovery and development
of newer ideas since this continuously aids in improving the
standards of treatment protocols and technologies. Over time, this
creates patient-friendly therapies with improved quality of life,
thus throwing North America in an
even more dominant position in the global peritoneal dialysis
market.
Request Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=211750966
Prominent players in this market include Baxter International
Inc. (US), Fresenius Medical Care AG (Germany), Medtronic plc (Ireland), Davita Inc. (US), Becton, Dickinson
and Company (US), Utah Medical Products, Inc. (US), Terumo
Corporation (Japan), Diaverum AB
(Sweden), Medionics (Canada), Newsol Technologies (Canada), Apollo Dialysis Pvt Ltd (India), U.S. Renal Care, Inc. (US), Northwest
Kidney Centers (US), Relavo (US), Mitra Industries Pvt Ltd
(India), JMS Co., Ltd.
(Japan), AMECATH (Egypt), Polymedicure (India), Huaren Pharmaceutical (China), AWAK Technologies (Singapore), Innovative Renal Care (US),
Romsons (India), SSEM Mthembu
Medical (Pty) Ltd (South
Africa), Renax Biomedical Technology Co., Ltd
(China), and Advin Health Care
(India).
BAXTER INTERNATIONAL INC.
(US):
Baxter has developed a strong
brand as well as from highly clinically superior products, such as
IV therapies and infusion pump solutions. R&D facilities for
the group exist in Belgium,
Sweden, India, Italy,
Germany, China, Japan,
and the US. In 2023, its kidney care division registered net sales
in the amount of USD 4.453 million,
and its contribution to the total revenue was 30.1%. In 2022,
Baxter started strategic review to
improve stockholder value by offering selling and carve-out
opportunities. In January 2023, the
company announced some key strategic steps; one of them was to spin
out Kidney Care as an independent, standalone, and publicly traded
kidney care company named Vantive. Baxter also agreed to simplify the company,
adjust its supply chain to operate more efficiently, and consider
alternatives for its BPS business. In August
2024, Carlyle agreed with the takeover of its Kidney Care
segment by Baxter; that marked the
end of creating Vantive. With these alterations, Baxter is focusing toward hospital solutions
and connected care and is trying to make the business model
streamlined through an aligned strategy that positions toward
innovation and ultimately delivers value to the stakeholders.
FRESENIUS MEDICAL CARE AG (GERMANY):
Fresenius Medical Care is one of the largest peritoneal dialysis
players in the world. The company differs according to its
comprehensive portfolio of dialysis products, remarkable R&D,
and presence around the globe. The company operates through 42
facilities in Asia Pacific,
North America, Europe, Latin
America, and Africa,
keeping a focus on partnership and agreement to seek further
opportunity. Fresenius puts emphasis on the advanced dialysis
products of renal therapies in developing the treatments for kidney
disease. This further reinforces its market position. It focuses on
purchases and acquisitions as well, as in the case of acquiring
InterWell Health in 2022, which guides the drive towards
innovation. The company operated 4,116 dialysis clinics at year-end
2022. Fifteen percent of U.S. patients are being treated in a home
setting, increasing to 25% by 2025. Fresenius invests its R&D
in innovative products, regenerative medicines, and the use of
digital technologies such as data analytics and remote monitoring
to optimize dialysis care.
MEDTRONIC PLC (IRELAND):
Medtronic Plc has some of the world's fastest-moving markets
with a requirement for constant innovation in order to stay at the
top. This brings about the focus of its R&D on advancing
technology, improving existing products and developing less
invasive solutions for emerging markets. The company participates
in hundreds of clinical trials per year in order to meet the demand
for clinical and economic evidence with a view to reducing costs
for patients and their hospital stays. The company focuses on
developing new therapies, extending the use of existing products,
and co-operation with third parties to take advantage of innovation
and improve the lives of patients. For instance, Medtronic in
partnership with Davita launched Mozarc Medical an independent firm
that would revolutionize kidney health through patient-centered
technology solutions in April
2023.
For more information, Inquire Now!
Related Reports:
Hemodialysis Market
Home Healthcare Market
Urology Devices Market
Medical Supplies Market
Top 10 Medical Device Technologies Market
Get access to the latest updates on Peritoneal Dialysis
Companies and Peritoneal Dialysis Market Size
About MarketsandMarkets™:
MarketsandMarkets™ has been recognized as one of America's
best management consulting firms by Forbes, as per their recent
report.
MarketsandMarkets™ is a blue ocean alternative in growth
consulting and program management, leveraging a man-machine
offering to drive supernormal growth for progressive organizations
in the B2B space. We have the widest lens on emerging technologies,
making us proficient in co-creating supernormal growth for
clients.
Earlier this year, we made a formal transformation into one of
America's best management consulting firms as per a survey
conducted by Forbes.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are
substituting existing revenue streams in this decade alone. We work
with clients on growth programs, helping them monetize this
$25 trillion opportunity through our
service lines - TAM Expansion, Go-to-Market (GTM) Strategy to
Execution, Market Share Gain, Account Enablement, and Thought
Leadership Marketing.
Built on the 'GIVE Growth' principle, we work with several
Forbes Global 2000 B2B companies - helping them stay relevant in a
disruptive ecosystem. Our insights and strategies are molded by our
industry experts, cutting-edge AI-powered Market Intelligence
Cloud, and years of research. The KnowledgeStore™ (our Market
Intelligence Cloud) integrates our research, facilitates an
analysis of interconnections through a set of applications, helping
clients look at the entire ecosystem and understand the revenue
shifts happening in their industry.
To find out more, visit www.MarketsandMarkets™.com or follow us
on Twitter, LinkedIn and Facebook.
Contact:
Mr. Rohan
Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL
33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
Logo:
https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jpg
View original
content:https://www.prnewswire.com/news-releases/peritoneal-dialysis-market-to-hit-usd-12-70-billion-by-2029-with-5-8-cagr--marketsandmarkets-302267586.html
SOURCE MarketsandMarkets